Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Post-Mkt 09-10 17:53:34 EDT

0.6612

+0.0173

+2.69%

盘后0.6496

-0.0116-1.75%

17:39 EDT

High0.6700	Low0.6260	Vol3.09M
Open0.6348	D1 Closing0.6439	Amplitude6.83%
Mkt Cap160.67M	Tradable Cap129.60M	Total Shares243.00M
T/O2.02M	T/O Rate1.57%	Tradable Shares196.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.6612,"timestamp":1789070400000,"preClose":0.6439,"halted":0,"volume":3085373,"hourTrading":{"tag":"盘后","latestPrice":0.6496,"preClose":0.6612,"latestTime":"17:39 EDT","volume":3950,"amount":2597.227542,"timestamp":1789076356738,"change":-0.0116,"changeRate":-0.017544,"amplitude":0.027223},"delay":0,"changeRate":0.026867526013356083,"floatShares":196000000,"shares":243000000,"eps":-0.747935,"marketStatus":"Post-Mkt","change":0.0173,"latestTime":"09-10 17:53:34 EDT","open":0.6348,"high":0.67,"low":0.626,"amount":2015228.9615761,"amplitude":0.068334,"askPrice":0.665,"askSize":20,"bidPrice":0.646,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.747935,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.6439,"preHourTrading":{"tag":"盘前","latestPrice":0.6331,"preClose":0.6439,"latestTime":"09:29 EDT","volume":86041,"amount":55365.22731254,"timestamp":1789046991132,"change":-0.0108,"changeRate":-0.016773,"amplitude":0.051095},"postHourTrading":{"tag":"盘后","latestPrice":0.6496,"preClose":0.6612,"latestTime":"17:39 EDT","volume":3950,"amount":2597.227542,"timestamp":1789076356738,"change":-0.0116,"changeRate":-0.017544,"amplitude":0.027223},"volumeRatio":0.613996,"impliedVol":0.5947,"impliedVolPercentile":0.247},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2666596987","title":"Outlook Therapeutics Wins FDA Approval for Lytenava in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596987","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596987?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:10","pubTimestamp":1789045841,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics wins FDA approval for LYTENAVA in wet AMDOutlook Therapeutics secured FDA approval for LYTENAVA, an ophthalmic bevacizumab formulation to treat wet age-related macular degeneratio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL5mc0dZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014039.USD","BK4112","OTLK","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","BK4585","IE00BQXX3F31.USD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BCDF","NDAQ","SG9999014021.USD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","BK4588","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666880599","title":"Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666880599","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666880599?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:10","pubTimestamp":1789045800,"startTime":"0","endTime":"0","summary":"Access the segmenthere ISELIN, N.J., Sept.  10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359613/0/en/outlook-therapeutics-ceo-bob-jahr-discusses-fda-approval-and-commercial-opportunity-for-lytenava-in-virtual-investor-ceo-connect-segment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849050","title":"Outlook Therapeutics CFO Kevin Michael Lundquist Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849050","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849050?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:31","pubTimestamp":1788381093,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics CFO Kevin Michael Lundquist files initial beneficial ownership statementOutlook Therapeutics CFO Kevin Michael Lundquist filed an initial Form 3 on Sept. 2, dated Sept. 1.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8HJw5W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662038652","title":"Outlook Therapeutics Names Kevin Lundquist CFO, Replacing Lawrence Kenyon","url":"https://stock-news.laohu8.com/highlight/detail?id=2662038652","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662038652?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:07","pubTimestamp":1787861240,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics names Kevin Lundquist CFO, replacing Lawrence KenyonOutlook Therapeutics named Kevin Lundquist chief financial officer, effective Sept. 1, 2026.Lundquist previously served as CFO ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL5hCk65:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BCDF","BK4588","BK4585","LU2210149790.SGD","LU2095319765.USD","IE00BQXX3C00.GBP","CV","IE00BN0W2W23.USD","SG9999014021.USD","BK4112","SG9999014039.USD","LU0314104364.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00BQXX3D17.EUR","BK4139","OTLK","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662603834","title":"Outlook Therapeutics - Lawrence Kenyon to Step Down as CFO Effective September 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662603834","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662603834?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:05","pubTimestamp":1787861100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA6HF0N7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662038375","title":"Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as it Prepares for U.S. Commercial Launch of Lytenava™","url":"https://stock-news.laohu8.com/highlight/detail?id=2662038375","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662038375?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:05","pubTimestamp":1787861100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA6HF0N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700792","title":"Outlook Therapeutics Posts CEO Bob Jahr “Why Now” Investor Conference Webcast on Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700792","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700792?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:03","pubTimestamp":1787835791,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics posts CEO Bob Jahr “Why Now” investor conference webcast on demandOutlook Therapeutics published an on-demand video webcast of CEO Bob Jahr’s Virtual Investor “Why Now” conference","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL7W43HN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014005.SGD","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","BK4585","BK4112","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014039.USD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","BCDF","SG9999014021.USD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014013.SGD","IE00BQXX3F31.USD","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660843471","title":"Outlook Therapeutics Delays Q2 Form 10-Q Filing After Finance Staff Turnover","url":"https://stock-news.laohu8.com/highlight/detail?id=2660843471","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660843471?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:06","pubTimestamp":1786997177,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics delays Q2 Form 10-Q filing after finance staff turnoverOutlook Therapeutics filed a Form 12b-25 to delay its quarterly Form 10-Q for the period ended June 30, 2026.Filing cited fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL4ptYQj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659120267","title":"Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear","url":"https://stock-news.laohu8.com/highlight/detail?id=2659120267","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659120267?lang=en_us&edition=fundamental","pubTime":"2026-08-15 13:26","pubTimestamp":1786771604,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics stock has had a very difficult five years, with the share price down about 98.3%, and the latest valuation checks currently do not flag the stock as a clear bargain despite this steep decline.\n\nOver the past five years, Outlook Therapeutics has declined around 98.3%, which means long term shareholders have seen most of their equity value eroded.\nThe recent approval and planned U.S. launch of LYTENAVA, supported by a US$55 million equity offering, can help fund growth but...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-otlk/outlook-therapeutics/news/outlook-therapeutics-otlk-stock-looks-fully-valued-while-boo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-otlk/outlook-therapeutics/news/outlook-therapeutics-otlk-stock-looks-fully-valued-while-boo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CDIG","TACU","OTLK","BK4139","TSPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659122189","title":"Outlook Therapeutics CFO Lawrence Kenyon Acquires 101,010 Common Shares Valued at $99,999.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2659122189","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659122189?lang=en_us&edition=fundamental","pubTime":"2026-08-15 07:40","pubTimestamp":1786750807,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9Outlook Therapeutics CFO Lawrence A. Kenyon bought 101,010 common shares in an underwritten public offering p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2ShvCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics CFO Lawrence Kenyon Acquires 101,010 Common Shares Valued at $99,999.9","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144024","title":"Outlook Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144024","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144024?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:31","pubTimestamp":1786714271,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryOutlook Therapeutics IncOTLK.OQreported a quarterly adjusted loss of 9 cents per share for the quarter ended Ju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659413145","title":"Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2659413145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659413145?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:26","pubTimestamp":1786706773,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Q3 net loss narrows slightly as costs dropOverviewU.S. biopharmaceutical firm's fiscal Q3 net loss narrowedCompany advancing U.S. launch strategy for LYTENAVA, FDA-approved ophtha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK","BK4505","BK4007","BK4539","LENZ","KOD","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659520145","title":"Outlook Therapeutics Q3 EPS USD -0.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2659520145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659520145?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:15","pubTimestamp":1786706145,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLXRZXHZ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659503145","title":"Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava™","url":"https://stock-news.laohu8.com/highlight/detail?id=2659503145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659503145?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:15","pubTimestamp":1786706100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA1M4KDS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659414569","title":"Press Release: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava(tm)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659414569","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659414569?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:15","pubTimestamp":1786706100,"startTime":"0","endTime":"0","summary":"The only FDA-approved ophthalmic bevacizumab, LYTENAVA(TM) , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely usedAdvancing the U.S. launch strategy for LYTE","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Press Release: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava(tm)","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659677115","title":"S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone","url":"https://stock-news.laohu8.com/highlight/detail?id=2659677115","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659677115?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:45","pubTimestamp":1786689942,"startTime":"0","endTime":"0","summary":"CNN Fear &amp; Greed index showed improved market sentiment, with S&amp;P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/08/61201145/sp-500-hits-new-record-high-following-ppi-data-investor-sentiment-improves-fear-index-remains-in-greed-zone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UXJL","VOO","CGUS","XPAY","FLCC","GBXB","GSUS","MRCP","PTLC","OALC","SSS","VYM","FLAO","SPDF","UXJA","VUG","HJUN","VSL","PTL","ABIG","PPI","XUSP","LGDX","LGH","CFO","ACLC","FELC","GPIX","SCHG","SPYM","UXAP","ISSXF","XSPI","VOOX","DSPY","UOCT","OTLK","BALY","VOOG","FEBT","CSCO","TSPA","USLX",".SPX","XXX","CPST","HELO","PBJL","BKLC","SPY","TOPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659075190","title":"Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2659075190","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659075190?lang=en_us&edition=fundamental","pubTime":"2026-08-14 13:30","pubTimestamp":1786685454,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119166","title":"U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119166","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659119166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:18","pubTimestamp":1786637899,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-EnerSys, Netflix, SalesforceAugust 13 (Reuters)-The S&P 500 hit an intraday record high on Thursday, boosted by technology stocks, as a drop in crude prices lifted risk ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEM","NFLX","LUNL","CGEM","FIVE","AVAH","ENS","OPEN","DIPR","ABEO","WSPC","STUB","DIOD","XLC","LESL","PYXS","CSCL","DKL","LWAY","GLNG","STAA","ABCL","IBM","CBRS","CRM","DERM","LNSR","MSGS","AKAM","AGMI","RKLX","CSCS","SPCE","TPR","CSCO","OMER","BIRK","DELL","WQTM","RKLB","TRUM","ARX","HLIT","HPQ","OTLK","CRMD","LUNR","MH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159403","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159403?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620654,"startTime":"0","endTime":"0","summary":"Leslie's (LESL) shares were down more than 42% premarket Thursday following the company's fiscal Q3 financial results.Valion Bio (VBIO) stock was 30% lower, continuing from a 27% fall in the prior ses","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NCPL","OTLK","BK4129","FGL","BK4082","BK4139","VBIO","LESL","BK4135","BK4200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659075134","title":"Outlook Therapeutics Prices $55 Million Securities Offering; Shares Down Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2659075134","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659075134?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:12","pubTimestamp":1786608759,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) priced a public offering of about 55.6 million common shares and accompanying warrants at $0.99 apiece, for $55 million in expected gross proceeds, the company said late We","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4539","OTLK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0281},{"period":"1month","weight":-0.4401},{"period":"3month","weight":-0.4146},{"period":"6month","weight":0.6343},{"period":"1year","weight":-0.3049},{"period":"ytd","weight":-0.5925}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.075556},{"month":7,"riseRate":0.545455,"avgChangeRate":0.003223},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.194294},{"month":9,"riseRate":0.545455,"avgChangeRate":0.045856},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}